.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,770,701

« Back to Dashboard

Details for Patent: 5,770,701

Title: Process for preparing targeted forms of methyltrithio antitumor agents
Abstract:This disclosure describes a method for constructing targeting agent drug conjugates from the family of methyltrithio antibacterial and antitumor agents.
Inventor(s): McGahren; William James (Demarest, NJ), Sassiver; Martin Leon (Spring Valley, NY), Ellestad; George A. (Pearl River, NY), Hamann; Philip R. (Garnerville, NY), Hinman; Lois M. (North Tarrytown, NY), Upeslacis; Janis (Pomona, NY)
Assignee: American Cyanamid Company (Madison, NJ)
Filing Date:Oct 26, 1994
Application Number:08/329,610
Claims:1. A process for preparing the targeted derivatives ##STR22## of compounds of formula CH.sub.3 SSS-W, wherein CH.sub.3 SSS-W is an N-acyl derivative of an antitumor antibiotic LL-E33288 .alpha..sub.a.sup.Br, .alpha..sub.2.sup.I, .beta..sub.1.sup.Br, .beta..sub.1.sup.I, .gamma..sub.1.sup.Br, .gamma..sub.1.sup.I, .delta..sub.1.sup.I, BBM-1675, FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E or CL-1724 wherein W is ##STR23## each of R.sub.4 and R.sub.7 independently is H or ##STR24## where R.sub.5 is CH.sub.3, C.sub.2 H.sub.5, or (CH.sub.3).sub.2 CH; X is an iodine or bromine atom; R.sup.5 is the group RCO wherein R is hydrogen or a branched or unbranched alkyl (C.sub.1 -C.sub.10) or alkylene (C.sub.1 -C.sub.10) group, an aryl or heteroarylgorup, or an aryl-alkyl (C.sub.1 -C.sub.5) or heteroaryl-alkyl (C.sub.1 -C.sub.5) group, all optionally substituted by one or more hydroxy, amino, carboxy, halo, nitro, lower (C.sub.1 -C.sub.3) alkoxy, or lower (C.sub.1 -C.sub.5) thioalkoxy groups, comprising

reacting CH.sub.3 SSS-W with a compound of formula Q-Sp-SH, wherein Sp is a straight or branched-chain divalent or trivalent (C.sub.1 -C.sub.18) radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl or heteroaryl radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl- or heteroaryl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.2 -C.sub.18) unsaturated alkyl radical, wherein heteroaryl is (4-methyl-coumarin-7yl)amino and wherein if Sp is a trivalent radical, it can be additionally substituted by amino, (C.sub.1 -C.sub.10) alkylamino, (C.sub.6 -C.sub.11) arylamino, heteroarylamino, carboxyl, lower alkoxy, hydroxy, thiol, or lower alkylthio groups; and Q is halogen, amino, C.sub.1 -C.sub.10 alkylamino, carboxyl, carboxaldehyde, hydroxy or lower alkyldicarboxyl anhydride in acetonitrile in the presence of one equivalent of triethylamine or one equivalent of triethylamine and one equivalent of acetic acid at -10.degree. to -30.degree. C. for 1-48 hours,

isolating the intermediate of formula Q-Sp-SS-W, wherein Q, Sp, and W are as hereinbefore defined, then reacting the compound of formula Q-Sp-SS-W, wherein Sp and W are as hereinbefore defined and Q is halogen, amino, alkylamino, carboxyl, carboxaldehyde, hydroxy, or lower alkyldicarboxylic anhydride with a molecule of the formula Tu-(Y).sub.n, wherein Tu-(Y).sub.n is a mono- or polyclonal antibody, its tumor-associated antigen-binding fragments, its chemically or genetically manipulated tumor-associated antigen-binding counterparts, or growth factors or steroids; Y is a side-chain amino or carboxy functionality of the antibody and n is 1-100, in aqueous buffer at a pH of between 6.5 and 9, at 40.degree. to 40.degree. C. either directly or in the presence of a water-soluble carbodiimide, to generate the compound ##STR25## wherein Tu, Sp, W, n, and Y are as hereinbefore defined, m is 1-15 and Z is formed from covalent reaction of the groups Q and Y and is --CONH--, --NH--, ##STR26## --N.dbd.CH--, or --CO.sub.2 --.

2. A process for preparing the targeted derivatives ##STR27## according to claim 1, comprising reacting the compound of formula Q-Sp-SS-W, wherein Sp is a straight or branched-chain divalent or trivalent (C.sub.1 -C.sub.18) radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl or heteroaryl radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl- or heteroaryl-alkyl (C.sub.4 -C18) radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.2 C,.sub.8) unsaturated alkyl radical, wherein heteroaryl is (4-methyl-coumarin-7-yl)amino and wherein if Sp is a trivalent radical, it can be additionally substituted by amino, (C.sub.1 -C.sub.10) alkylamino, (C.sub.6 -C.sub.11)arylamino, heteroarylamino, carboxyl, lower alkoxy, hydroxy, thiol, or lower alkylthio groups; W is as defined in claim 1 and Q is a carboxylic acid, with N-hydroxysuccinimide, 2,3,5,6- tetrafluorophenol, pentafluorophenol, or 4-nitrophenol in the presence of carbodiimide to generate a compound of formula Q-Sp-SS-W wherein Sp and W are as hereinbefore defined and Q is ##STR28## with a molecule of formula Tu-(Y).sub.n, where Tu is a mono- or polyclonal antibody, its tumor associated antigen-binding fragments, its chemically or genetically manipulated tumor-associated antigen-binding counterparts, or growth factors or steroids; Y is a side-chain amino; n is 1-100, in an aqueous buffered solution at a pH between 6.5 and 9, at a temperature of between 4.degree. and 40.degree. C., inclusive, to generate compounds of the formula: ##STR29## wherein Tu, Sp, Y, and n are as hereinbefore defined, m is 1-15, and Z is formed from covalent reaction between Q and Y and is defined as --CONH--.

3. A process according to claim 2 for producing a targeted compound compound ##STR30## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with .beta.-mercaptopropionic acid at -20.degree. C. in acetonitrile in the presence of a tertiary amine base, isolating the intermediate product and reacting the intermediate product with N-hydroxysuccinimide in the presence of dicyclohexylcarbodiimide in tetrahydrofuran at ambient temperature for about four hours, isolating the intermediate, and reacting it with a monoclonal antibody in a buffered solution at pH 7.5 for 1 to 4 hours to produce the compound of the formula, above, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --NHCO--, Sp is --CH.sub.2 --CH.sub.2 --, (Y).sub.n-m is NH.sub.2 of the antibody, and m is 2 to 15.

4. A process according to claim 2 for producing a targeted compound ##STR31## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with 3-mercaptobutyric acid at -20.degree. C. in acetonitrile in the presence of a tertiary amine base, isolating the intermediate product, and reacting the intermediate product with N-hydroxysuccinimide in the presence of dicyclohexylcarbodiimide in tetrahydrofuran at ambient temperature for about four hours, isolating the intermediate, and reacting it with a monoclonal antibody in a buffered solution at pH 7.5 for 1 to 4 hours, to produce the compound of the formula, above, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --NHCO--, Sp is --CH.sub.2 --CH(CH.sub.3)--, (Y).sub.n-m is --NH.sub.2 of the antibody, and m is 2 to 15.

5. A process according to claim 2 for producing a targeted compound ##STR32## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with 3-mercaptoisovaleric acid at -20.degree. C. in acetonitrile in the presence of a tertiary amine base, isolating the intermediate product, and reacting the intermediate product with N-hydroxysuccinimide in the presence of dicyclohexylcarbodiimide in tetrahydrofuran at ambient temperature for about four hours, isolating the intermediate, and reacting it with a monoclonal antibody in a buffered solution at pH 7.5 for 1 to 4 hours, to produce the compound of the formula, above, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --NHCO--, SP is --CH.sub.2 C (CH.sub.3).sub.2, (Y).sub.n-m is --NH.sub.2 of the antibody, and m is 2 to 15.

6. A process according to claim 2 for producing a targeted compound ##STR33## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with p-mercaptodihydrocinnamic acid at -20.degree. C. in acetonitrile in the presence of a tertiary amine base, isolating the intermediate product and reacting the intermediate product with N-hydroxysuccinimide in the presence of dicyclohexylcarbodiimide in tetrahydrofuran at ambient temperature for about four hours, isolating the intermediate, and reacting it with a monoclonal antibody in a buffered solution at pH 7.5 for 1 to 4 hours, to produce the compound of the formula, above, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --NHCO--, Sp is ##STR34## (Y).sub.n-m is --NH.sub.2 of the antibody, and m is 2 to 15.

7. A process according to claim 2 for producing a targeted compound ##STR35## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with N[[(4-methylcoumarin-7-yl)amino]acetyl]cysteine at -20.degree. C. in acetonitrile in the presence of a tertiary amine base, isolating the intermediate product and reacting the intermediate product with N-hydroxysuccinimide in the presence of dicyclohexylcarbodiimide in tetrahydrofuran at ambient temperature for about four hours, isolating the intermediate, and reacting it with a monoclonal antibody in a buffered solution at pH 7.5 for 1 to 4 hours, to produce the compound of the formula, above, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --NHCO, -Sp is ##STR36## (Y).sub.n-m is --NH.sub.2 of the antibody, and m is 2 to 15.

8. A process for preparing the targeted derivatives of compounds of formula CH.sub.3 SSS-W, wherein CH.sub.3 SSS-W is an N-acyl derivative of an antitumor antibiotic LL-E33288 .alpha..sub.2.sup.Br, .alpha..sub.2.sup.I, .beta..sub.1.sup.Br, .beta..sub.1.sup.I, .gamma..sub.1.sup.Br, .gamma..sub.1.sup.I, .delta..sub.1.sup.I, BBM-1675, FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E or CL-1724 wherein W is ##STR37## each of R.sub.6 and R.sub.7 independently is H or ##STR38## where R.sub.5 is CH.sub.3, C.sub.2 H.sub.5, or (CH.sub.3).sub.2 CH; X is an iodine or bromine atom; R.sub.5 is the group RCO wherein R is hydrogen or a branched or unbranched alkyl (C.sub.1 -C.sub.10) or alkylene (C.sub.1 -C.sub.10) group, an aryl or heteroaryl group, or an aryl-alkyl (C.sub.1 -C.sub.5) or heteroaryl-alkyl (C.sub.1 -C.sub.5) group, all optionally substituted by one or more hydroxy, amino, carboxy, halo, nitro, lower (C.sub.1 -C.sub.3, alkoxy, or lower (C.sub.1 -C.sub.5) thioalkoxy groups, comprising

reacting the compound of formula Q-Sp-SS-W, wherein Sp is a straight or branched-chain divalent or trivalent (C.sub.1 -C.sub.18) radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl or heteroaryl radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl- or heteroaryl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.2 -C.sub.18) unsaturated alkyl radical, wherein heteroaryl is (4-methyl-coumarin-7-yl)amino and wherein if Sp is a trivalent radical, it can be additionally substituted by amino, (C.sub.1 -C.sub.10) alkylamino, (C.sub.6 -C.sub.11) arylamino, heteroarylamino, carboxyl, lower alkoxy, hydroxy, thiol, or lower alkylthio groups; and Q is --NH.sub.2, --CONHNH.sub.2, --NHCONHNH.sub.2, --NHCSNHNH.sub.2, or --ONH.sub.2 with a molecule of formula Tu-(Y).sub.n wherein Tu is a mono- or polyclonal antibody, its tumor-associated antigen-binding fragments, its chemically or genetically manipulated tumor-associated antigen-binding counterparts, or growth factors or steroids;

Y is an aldehyde generated from carbohydrate residues on Tu by oxidation in the presence of an alkaline earth periodate, in an aqueous buffer at a pH between 4.0 and 6.5 at 4.degree. to 40.degree. C., inclusive, and n is 1 to 20 to generate a compound of formula: ##STR39## wherein Tu, Sp, W, Y, and n are as hereinbefore defined and Z is formed from the covalent reaction of Q and Y and is --ON.dbd.CH--, --N.dbd.CH--, --CONHN.dbd.CH--, --NHCONHN.dbd.CH--, or --NHCSNHN.dbd.CH--, and m is 0.1 to 15.

9. A process for preparing the targeted derivatives ##STR40## of compounds of formula CH.sub.3 SSS-W, wherein CH.sub.3 SSS-W is an N-acyl derivative of an antitumor antibiotic LL-E33288 .alpha..sub.2.sup.Br, .alpha..sub.2.sup.I, .beta..sub.1.sup.Br, .gamma..sub.1.sup.I, .gamma..sub.1.sup.Br, .gamma..sub.1 BBM-1675, FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E or CL-1724 wherein W is ##STR41## each of R.sub.6 and R.sub.7 independently is H or ##STR42## where R.sub.5 is CH.sub.3, C.sub.2 H.sub.5, or (CH.sub.3).sub.2 CH; X is an iodine or bromine atom; R.sub.5' is the group RCO wherein R is hydrogen or a branched or unbranched alkyl (C.sub.1 -C.sub.10) or alkylene (C.sub.1 -C.sub.10) group an aryl or heteroaryl group, or an aryl-alkyl (C.sub.1 -C.sub.5) or heteroaryl-alkyl (C.sub.1 -C.sub.5) group, all optionally substituted by one or more hydroxy, amino, carboxy halo, nitro, lower (C.sub.1 -C.sub.3) alkoxy, or lower (C.sub.1 -C.sub.5) thioalkoxy groups, comprising

reacting the compound of formula Q-Sp-SS-W, wherein Sp is a straight or branched-chain divalent or trivalent (C.sub.1 -C.sub.5) radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl or heteroaryl radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl or heteroaryl-alkyl (C.sub.2 -C.sub.18) radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalky heterocycloalkyl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.2 -C.sub.18) unsaturated alkyl radical, wherein heteroaryl is (4-methyl-coumarin-7-yl)amino and wherein if Sp is a trivalent radical, it can be additionally substituted by amino, (C.sub.1 -C.sub.10) alkylamino, (C.sub.6 -C.sub.11) arylamino, heteroarylamino, carboxyl, lower alkoxy, hydroxy, thiol, or lower alkylthio groups; and Q is --NH.sub.2, --CONHNH.sub.2, --NHCONHNH.sub.2, --NHCSNHNH.sub.2, or --ONH.sub.2 with a molecule of formula Tu-(Y).sub.n wherein Tu is a mono- or polyclonal antibody, its tumor-associated antigen-binding fragments, its chemically or genetically manipulated tumor-associated antigen-binding counterparts, or growth factors or steroids;

Y is an aldehyde generated from carbohydrate residues of the antibody by oxidation in the presence of an alkaline earth periodate, in an aqueous buffer at a pH between 4.0 and 6.5, at 4.degree. to 40.degree. C., inclusive, and n is 1 to 20 to generate a compound of formula: ##STR43## wherein Tu, Sp, W, Y, and n are as hereinbefore defined and Z is formed form the covalent reaction of Q and Y and is --ON.dbd.CH--, --N.dbd.CH--, --CONHN.dbd.CH--, or --NHCSNHN.dbd.CH--, and m is 0.1 to 15; and treating the compound immediately hereinabove of formula: ##STR44## wherein Tu, Z, Sp, W, Y, n, and m are as immediately hereinabove defined with acteylhydrazine or tyrosine hydrazine in an aqueous buffer at a pH between 4.0 and 6.5, at 4.degree. to 40.degree. C., inclusive, to generate a compound of formula: ##STR45## wherein Tu, Z, Sp, W, n, and m are as immediately hereinabove defined and Y is --CH.dbd.NNHCOCH.sub.3 or ##STR46## and reacting this compound with sodium cyanoborohydride or sodium borohydride, in an aqueous buffer at a pH of 4.0 to 6.5, at a temperature of 4.degree. to 40.degree. C., inclusive, to generate a compound of formula: ##STR47## wherein Tu, Sp, W, m, and n are as hereinabove defined, Z is --NH--CH.sub.2 --, --CONHNHCH.sub.2 --, --NHCONHNHCH.sub.2 --, or --NHCSNHNHCH.sub.2 --, and Y is --CH.sub.2 NHNHCOCH.sub.3 or ##STR48##

10. A process according to claim 8 for producing a targeted compound of the formula ##STR49## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with .beta.-mercaptobutyric acid hydrazide at -15.degree. in tetrahydrofuran in the presence of a tertiary amine base for from one to 36 hours, isolating the intermediate product and reacting the intermediate product with a monoclonal antibody which was oxidized with sodium periodate in acetate buffer, at a pH of 5.5 to 7.0 at 4.degree. C. for about 45 minutes and dialyzed to remove excess sodium periodate, to produce the compound of the formula, above, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --CH.dbd.NNHCO--, Sp is --CH.sub.2 --CH.sub.2 --, (Y).sub.n-m is CHO of the antibody, and m is 1 to 10.

11. A process according to claim 8 for producing a targeted compound of the formula ##STR50## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with .beta.-mercaptopropionic acid hydrazide at -15.degree. in tetrahydrofuran in the presence of a tertiary amine base for from one to 36 hours, isolating the intermediate product and reacting the intermediate product with a monoclonal antibody which was oxidized with sodium periodate in acetate buffer at a pH of 5.5 to 7.0 at 4.degree. C. for about 45 minutes and dialyzed to remove excess sodium periodate, to produce the compound of the formula, above, where Tu-(Y).sub.n-m is the monoclonal antibody, Z is --CH.dbd.NNHCO--, Sp is --CH.sub.2 --C(CH.sub.3)--, (Y).sub.n-m is CHO of the antibody, and m is 1 to 10.

12. A process according to claim 8 for producing a targeted compound of the formula ##STR51## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with 3-mercaptoisovaleric acid hydrazide at -15.degree. in tetrahydrofuran in the presence of a tertiary amine base for from one to 36 hours, isolating the intermediate product and reacting the intermediate product with a monoclonal antibody which was oxidized with sodium periodate in acetate buffer, at a pH of 5.5 to 7.0 at 4.degree. C. for about 45 minutes and dialyzed to remove excess sodium periodate, to produce the compound of the formula, above, wherein Tu-(Y).sub.nm is the monoclonal antibody, Z is --CH.dbd.NNHCO--, Sp is --CH.sub.2 C(CH.sub.3).sub.2 --, (Y).sub.n-m is CHO of the antibody, and m is 1 to 10.

13. A process according to claim 8 for producing a targeted compound of the formula ##STR52## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with p-mercaptodihydrocinnamic acid hydrazide at -15.degree. in tetrahydrofuran in the presence of a tertiary amine base for from one to 36 hours, isolating the intermediate product and reacting the intermediate product with a monoclonal antibody which was oxidized with sodium periodate in acetate buffer, at a pH of 5.5 to 7.0 at 4.degree. C. for about 45 minutes and dialyzed to remove excess sodium periodate, to produce the compound of the formula, above, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --CH.dbd.NNHCO--, Sp is ##STR53## (Y).sub.n-m is CHO of the antibody, and m is 1 to 10.

14. A process according to claim 8 for producing a targeted compound of the formula ##STR54## from N-acetyl-LL-E33288.sub..gamma.1.sup.I of the formula CH.sub.3 SSS-W comprising reacting N-acetyl-LL-E33288.sub..gamma.1.sup.I with N-[[(4-methylcoumaryl-7-yl)amino]acetyl]cysteine hydrazide at -15.degree. in tetrahydrofuran in the presence of a tertiary amine base for from one to 36 hours, isolating the intermediate product and reacting the intermediate product with a monoclonal antibody which was oxidized with sodium periodate in acetate buffer, at a pH of 5.5 to 7.0 at 4.degree. C. for about 45 minutes and dialyzed to remove excess sodium periodate, to produce the compound of the formula, above, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --CH=NNHCO--, Sp is ##STR55## (Y).sub.n-m is CHO of the antibody, and m is 1 to 10.

15. A process according to claim 9, wherein unreacted aldehyde groups are blocked by reaction with acetyl hydrazine for about 3 hours followed by reduction with sodium cyanoborohydride to produce the compound of the formula of claim 7, wherein Tu-(Y).sub.n-m is the monoclonal antibody, Z is --CH.sub.2 NHNNCO--, Sp is --CH.sub.2 CH.sub.2 --, (Y).sub.n-m is --CH.sub.2 NHNHCOCH.sub.3, and m is 1 to 10.

16. A process according to claim 9, wherein unreacted aldehyde groups are blocked by reaction with acetyl hydrazine for about 3 hours followed by reduction with sodium cyanoborohydride to produce the compound of the formula, of claim 9, wherein Tu is the monoclonal antibody, Z is --CH.sub.2 NHNHCO--, Sp is --CH.sub.2 CH(CH.sub.3)--, Y is --CH.sub.2 NHNHCOCH.sub.3, and m is 1 to 10.

17. A process according to claim 9, wherein unreacted aldehyde groups are blocked by reaction with acetyl hydrazine for about 3 hours followed by reduction with sodium cyanoborohydride to produce the compound of the formula, of claim 9, wherein Tu is the monoclonal antibody, Z is --CH.sub.2 NHNHCO--, Sp is --CH.sub.2 C(CH.sub.3).sub.2, Y is --CH.sub.2 NHNHCOCH.sub.3, and m is 1 to 10.

18. A process according to claim 9, wherein unreacted aldehyde groups are blocked by reaction with acetyl hydrazine for about 3 hours followed by reduction with sodium cyanoborohydride to produce the compound of the formula of claim 9, wherein Tu is the monoclonal antibody, Z is --CH.sub.2 NHNHCO--, Sp is ##STR56## Y is --CH.sub.2 NHNHCOCH.sub.3, and m is 1 to 10.

19. A process according to claim 9, wherein unreacted aldehyde groups are blocked by reaction with acetyl hydrazine for about 3 hours followed by reduction with sodium cyanoborohydride to produce the compound of the formula of claim 9, wherein Tu is the monoclonal antibody, Z is --CH.sub.2 NHNHCO--, Sp is ##STR57## Y is --CH.sub.2 NHNHCOCH.sub.3, and m is 1 to 10.

20. A process for preparing the targeted derivatives ##STR58## of compounds of formula CH.sub.3 SSS-W wherein CH.sub.3 SSS-W is an N-acyl derivative of an antitumor antibiotic LL-E33288 .alpha..sub.2.sup.Br, .alpha..sub.2.sup.I, .beta..sub.1.sup.Br, .beta..sub.1.sup.I, .gamma..sub.1.sup.Br, .gamma..sub.1.sup.I, .delta..sub.1.sup.I, BBM-1675, FR-900405, FR-900406, PD 114759, PD 115028 CL-1577A, CL-1577B, CL-1577D, CL-1577E wherein W is ##STR59## each of R.sub.6 and R.sub.7 independenty is H or ##STR60## where R.sub.5 is CH.sub.3, C.sub.2 H.sub.5, or (CH.sub.3).sub.2 CH; X is an iodine or bromine atom; R.sub.5 is the group wherein R is hydrogen or a branched or unbranched alkyl (C.sub.1 -C.sub.10) or alkylene (C.sub.1 -C.sub.10) group, an aryl or heteroaryl group, or an aryl-alkyl (C.sub.1 -C.sub.5) or heteroaryl-alkyl (C.sub.1 -C.sub.5) group, all optionally substituted by one or more hydroxy, amino, carboxy, halo, nitro, lower (C.sub.1 -C.sub.3) alkoxy, or lower (C.sub.1 -C.sub.5) thioalkoxy groups, comprising

reacting the compound of formula Q-Sp-SS-W, wherein Sp is a straight or branched-chain divalent or trivalent (C.sub.1 -C.sub.18 radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl or heteroaryl radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl or heteroaryl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.2 -C.sub.18) unsaturated alkyl radical, wherein heteroaryl is (4-methyl-coumarin-7-yl)amino and wherein if Sp is a trivalent radical, it can be additionally substituted by amino, (C.sub.1 -C.sub.10) alkylamino, (C.sub.6 -C.sub.11) arylamino, heteroarylamino, carboxyl, lower alkoxy, hydroxy, thiol, or lower alkylthio groups; and Q is --CONHNH.sub.2, with nitrous acid in aqueous acetonitrile to generate a compound of formula Q-Sp-SS-W, wherein Sp and W are as hereinbefore defined and Q is --CON.sub.3 with a compound of formula Tu-(Y).sub.n, wherein Tu is a mono- or polyclonal antibody, its tumor-associated antigen-binding fragments, its chemically or genetically manipulated tumor-associated antigen-binding counterparts, or growth factors or steroids; Y is a side-chain amino functionality; and n is 1-100, to produce a compound of the formula ##STR61## wherein Tu, Z, Sp, W, m, Y, and n are as hereinabove defined.

21. A process for preparing the targeted derivatives ##STR62## of compounds of formula CH.sub.3 SSS-W wherein CH.sub.3 SSS-W is an N-acyl derivative of an antitumor antibiotic LL-E33288 .alpha..sub.a.sup.Br, .alpha..sub.2.sup.I, .beta..sub.1.sup.Br, .beta..sub.1.sup.I, .gamma..sub.1.sup.Br, .gamma..sub.1 BBM-1675, FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E or CL-1724 wherein W is ##STR63## each of R.sub.6 and R.sub.7 independently is H or ##STR64## where R.sub.5 is CH.sub.3, C.sub.2 H.sub.5, or (CH.sub.3).sub.2 CH; X is an iodine or bromine atom; R.sub.5' is the group RCO wherein R is hydrogen or a branched or unbranched alkyl (C.sub.1 -C.sub.10) or alkylene (C.sub.1 -C.sub.10) group, an aryl or heteroaryl group, or an aryl-alkyl (C.sub.1 -C.sub.5) or heteroaryl-alkyl (C.sub.1 -C.sub.5) group, all optionally substituted by one or more hydroxy, amino, carboxy, halo, nitro, lower (C.sub.1 -C.sub.3) alkoxy, or lower (C.sub.1 -C.sub.5) thioalkoxy groups, comprising

reacting the compound of formula Q-Sp-SS-W, wherein Sp is a straight or branched-chain divalent or trivalent (C.sub.1 -C.sub.18) radical, divalent or trivalent (C.sub.6 -C.sub.11) aryl or heteroaryl radical, divalent or trivalent (C.sub.3 -C.sub.18) cycloalkyl or heterocycloalkyl radical, divalent or trivalent heterocycloalkyl-alkyl (C.sub.4 -C.sub.18) radical, divalent or trivalent (C.sub.2 -C.sub.18) unsaturated alkyl radical, wherein heteroaryl is (4-methyl-coumarin-7-yl)amino and wherein if Sp is a trivalent radical, it can be additionally substituted by amino, (C.sub.1 -C.sub.10) alkylamino, (C.sub.6 -C.sub.11) arylamino, heteroarylamino, carboxyl, lower alkoxy, hydroxy, thiol, or lower alkylthio groups; and Q is hydroxy, with an alpha-haloacetic anhydride to produce a compound wherein Q is .alpha.-haloacetyloxy, and reacting the .alpha.-haloacetyloxy-Sp-SS-W, or a compound of formula Q-SP-SS-W, wherein Sp and W are as hereinbefore defined and Q is ##STR65## with a molecule of the formula Tu-(Y).sub.n wherein Tu is a mono- or polyclonal antibody, its tumor-associated antigen-binding fragments, its chemically or genetically manipulated tumor-associated antigen-binding counterparts, or growth factors or steroids;

Y is a side-chain thiol of a protein, or an amidoalkylthio group introduced on an amine of Tu using reagents for introducing thiol groups followed by reduction with an agent which generates the thiol group, above, or an amidoalkylthio group introduced on an amine of Tu using 2-iminothiolane, and n is 1-10, under aqueous buffered conditions at a pH between 4.5 and 7, at a temperature between 4.degree. and 40.degree. C., inclusive, to produce a compound of the formula: ##STR66## wherein Tu, Sp, W, and n are as hereinbefore defined, and Z is formed from covalent reaction of the Q and Y and Z is ##STR67##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc